A practical reference on thymic extract: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
==== Commonly associated with weight loss ==== Common gastrointestinal disorders associated with weight loss are malabsorption due to Celiac disease or chronic pancreatitis. Depression and eating disorders such as anorexia nervosa can also contribute to weight loss. Infectious causes of weight loss include HIV/AIDS. While Type 1 diabetes has been found to cause weight loss, type 2 diabetes has been associated with weight gain. Other endocrine causes of weight loss include hyperthyroidism and chronic adrenal insufficiency.
=== Extraction === If the protein of interest is not secreted by the organism into the surrounding solution, the first step of each purification process is the disruption of the cells containing the protein. Depending on how fragile the protein is and how stable the cells are, one could, for instance, use one of the following methods: i) repeated freezing and thawing, ii) sonication, iii) homogenization by high pressure (French press), iv) homogenization by grinding (bead mill), and v) permeabilization by detergents (e.g. Triton X-100) and/or enzymes (e.g. lysozyme). Finally, the cell debris can be removed by differential centrifugation, which is a procedure where the homogenate is centrifuged at low speed, then again at a greater force to yield a pellet consisting of nuclei and supernatant. This yields several fractions of decreasing density where more discriminating purification techniques are applied to one fraction. Also, proteases are released during cell lysis, which will start digesting the proteins in the solution. If the protein of interest is sensitive to proteolysis, it is recommended to proceed quickly, and to keep the extract cooled, to slow down the digestion. Alternatively, one or more protease inhibitors can be added to the lysis buffer immediately before cell disruption. Sometimes it is also necessary to add DNAse in order to reduce the viscosity of the cell lysate caused by a high DNA content.
Until the 1960s, radioactivity was often handled naively and carelessly. From 1940 to 1945, the Berlin-based Auergesellschaft, founded by Carl Auer von Welsbach (1858-1929, Osram), produced a radioactive toothpaste called Doramad that contained thorium-X and was sold internationally. It was advertised with the statement, "Its radioactive radiation strengthens the defenses of the teeth and gums. The cells are charged with new life energy and the destructive effect of bacteria is inhibited. This gave the claim of radiant white teeth a double meaning. By 1930, there were also bath additives and eczema ointments under the brand name "Thorium-X". Radium was also added to toothpastes, such as Kolynos toothpaste. After World War I, radioactivity became a symbol of modern achievement and was considered "chic". Radioactive substances were added to mineral water, condoms, and cosmetic powders. Even chocolate laced with radium was sold. The toy manufacturer Märklin in the Swabian town of Göppingen tested the sale of an X-ray machine for children. At upper-class parties, people "photographed" each other's bones for fun. A system called Trycho (Ancient Greek: τριχο-, romanized: tricho-, lit. 'concerning the hair') for epilation (hair removal) of the face and body was franchised in the USA. As a result, thousands of women suffered skin burns, ulcers and tumors. It was not until the atomic bombings of Hiroshima and Nagasaki that the public became aware of the dangers of ionizing radiation and these products were banned.
== History and Development == Tagging technology and instrument development occurred at the University of Toronto and DVS Sciences, Inc. CyTOF (cytometry by time of flight) was initially commercialized by DVS Sciences in 2009. In 2014, Fluidigm acquired DVS Sciences to become a reference company in single cell technology. The technology evolved through models like CyTOF, CyTOF2, Helios (CyTOF3) and CyTOF XT, with the latter announced in 2021. In 2022 Fluidigm received a capitol infusion and changed its name to Standard BioTools. In 2023, Standard BioTools introduced the Hyperion XTi Imaging System, advancing Imaging Mass Cytometry (IMC) with capabilities such as whole slide imaging, automated sample processing, and dual imaging/flow cytometry modes. In 2024, the company expanded its high-throughput imaging options with two additional rapid modes and an automated slide loader that can be installed directly on the Hyperion XTi for automatic loading and acquisition of up to 40 slides. Additionally, a 2024 collaboration with Navignostics was announced to develop clinical research applications using the Hyperion XTi system . In 2025, Standard BioTools announced the CyTOF XT Pro System, streamlining workflow with up to 4x faster throughput and software with 21 CFR Part 11 compliance enabling features.
== Chemistry == Levobunolol is the pure L-enantiomer of bunolol and has more than 60 times the pharmacological activity of D-bunolol. It is used as the hydrochloride, which melts at 209 to 211 °C (408 to 412 °F) and is soluble in water and methanol and slightly soluble in ethanol.
Sources: en.wikipedia.org
10 October – After making contact with his parents-in-law in Gaza, Humza Yousaf calls for a humanitarian corridor to be established. 11 October – Sean Hogg, who was given a 270-hour community order after being found guilty of twice raping a 13-year-old girl when he was 17, has the conviction quashed on appeal after prosecutors admit making mistakes during the original trial. Police are investigating fresh revelations about the Bible John killings after a podcast, Bible John: Portrait of the Serial Killer, alleged a cover up by police at the time, and that the perpetrator could be John Irvine McInnes, the cousin of a senior police officer. 12 October – Lisa Cameron, MP for East Kilbride, Strathaven and Lesmahagow, crosses the floor from the SNP to the Conservatives citing "a "toxic" culture in the SNP's Westminster group". Edinburgh Sheriff Court orders the extradition of Holocaust denier Vincent Reynouard, who faces trial in France for challenging the existence of crimes against humanity. Aberdeen City Councillor Kairin van Sweeden refers herself to the Standards Commission after describing a fellow councillor who was born in Sri Lanka as a "New Scot" during a council meeting. 13 October – After sharing a video of his mother-in-law, Elizabeth El-Nakla, describing the situation in Gaza, First Minister Humza Yousaf says that Israel is "going too far" and that innocent civilians can not simply be "collateral damage".
Each component interacts with the stationary phase in a different manner depending upon its polarity and hydrophobicity. In reverse phase HPLC, the solute with the greatest polarity will interact less with the stationary phase and spend more time in the mobile phase. As the polarity of the components decreases, the time spent in the column increases. Thus, a separation of components is achieved based on polarity. The addition of micelles to the mobile phase introduces a third phase into which the solutes may partition.
Structural alignment attempts to establish homology between two or more polymer structures based on their shape and three-dimensional conformation. This process is usually applied to protein tertiary structures but can also be used for large RNA molecules. In contrast to simple structural superposition, where at least some equivalent residues of the two structures are known, structural alignment requires no a priori knowledge of equivalent positions. Structural alignment is a valuable tool for the comparison of proteins with low sequence similarity, where evolutionary relationships between proteins cannot be easily detected by standard sequence alignment techniques. Structural alignment can therefore be used to infer evolutionary relationships between proteins that share very little common sequence. Those relationships can then be characterized through structural phylogenetics. However, caution should be taken when interpreting any results as evidence for shared evolutionary ancestry due to the potential confounding effects of convergent evolution, by which unrelated or distantly-related amino acid sequences converge on a common tertiary structure. Structural alignments can compare two sequences or multiple sequences. Because these alignments rely on information about all the query sequences' three-dimensional conformations, the method can only be used on sequences where these structures are known. These are usually found by X-ray crystallography or NMR spectroscopy. It is possible to perform a structural alignment on structures produced by structure prediction methods.
A common example of backpressure is that caused by the exhaust system (consisting of the exhaust manifold, catalytic converter, muffler and connecting pipes) of an automotive four-stroke engine, which has a negative effect on engine efficiency, resulting in a decrease of power output that must be compensated by increasing fuel consumption. In a piston-ported two-stroke engine, however, the situation is more complicated, due to the need to prevent unburned fuel/air mixture from passing right through the cylinders into the exhaust. During the exhaust phase of the cycle, backpressure is even more undesirable than in a four-stroke engine, as there is less time available for exhaust and the lack of pumping action from the piston to force the exhaust out of the cylinder. However, since the exhaust port necessarily remains open for a time after scavenging is completed, unburned mixture can follow the exhaust out of the cylinder, wasting fuel and increasing pollution. This can only be prevented if the pressure at the exhaust port is greater than that in the cylinder. Since the timing of this process is determined mainly by exhaust system geometry, which is extremely difficult to make variable, correct timing and therefore optimum engine efficiency can typically only be achieved over a small part of the engine's range of operating speed.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.